Johnson & Johnson (NYSE:JNJ) Trading 1.1% Higher – What’s Next?

Johnson & Johnson (NYSE:JNJ) rose 1.1% on Monday . The company traded as high as $273.98 and last traded at $273.1140. 5,411,035 shares were traded during trading, a decline of 34% from the average session volume of 8,241,688 shares. The stock had previously closed at $270.24.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The European Commission approved a TECVAYLI combination for multiple myeloma, expanding access to J&J’s oncology portfolio and potentially supporting future pharmaceutical sales. Johnson & Johnson Wins EU Approval for TECVAYLI Combo
• Positive Sentiment: Analysts highlighted J&J’s pipeline momentum, including new product launches, late-stage clinical data and additional approvals. These catalysts could help offset the loss of exclusivity affecting older drugs and support growth through 2026 and beyond. J&J’s Strong Pipeline Momentum Offers Multiple Growth Catalysts Ahead
• Positive Sentiment: Recent comparisons with other healthcare companies characterized J&J as a relatively defensive business with growth potential from its pharmaceutical and medical-technology operations. Its latest reported quarter also showed revenue growth and an earnings beat, while full-year 2026 EPS guidance remains $11.60–$11.75.
• Neutral Sentiment: J&J’s proposed $5.5 billion settlement covering tens of thousands of talc-related ovarian-cancer claims could improve visibility into a long-running liability, but the settlement is not a complete resolution of the company’s legal exposure. J&J’s $5.5 Billion Talc Settlement
• Negative Sentiment: A Louisiana jury awarded $10 million in a talc-related mesothelioma case involving a former user of J&J talc products. Although the award is small relative to J&J’s market capitalization, it reinforces continuing litigation and headline risk. Louisiana Jury Issues $10 Million Verdict
• Negative Sentiment: J&J is already experiencing rapid erosion of Stelara revenue as competitors and biosimilars challenge the drug after loss of exclusivity. Investors must therefore determine whether newer medicines and pipeline products can replace the declining franchise. Pfizer vs. Johnson & Johnson Patent Cliff Comparison

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Morgan Stanley raised their target price on shares of Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a research note on Thursday, July 16th. TD Cowen lifted their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Bank of America boosted their price objective on Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a report on Friday, July 10th. Scotiabank reiterated an “outperform” rating and issued a $305.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $268.22.

Johnson & Johnson Trading Up 1.1%

The company has a market cap of $658.18 billion, a PE ratio of 31.65, a PEG ratio of 2.58 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The company has a 50 day simple moving average of $255.08 and a two-hundred day simple moving average of $242.80.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Sell-side analysts forecast that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s payout ratio is currently 62.11%.

Insider Transactions at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 63,972 shares of company stock worth $16,245,605. 0.16% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Blueline Advisors LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at $25,000. Cresta Advisors Ltd. bought a new stake in Johnson & Johnson during the fourth quarter valued at about $26,000. Outlook Capital Management LLC bought a new position in shares of Johnson & Johnson in the second quarter worth about $28,000. DecisionPoint Financial LLC lifted its position in shares of Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares during the last quarter. Finally, Bay Harbor Wealth Management LLC lifted its position in shares of Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after purchasing an additional 49 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.